MAIA says updated lung cancer data could support an accelerated approval filing
The small-cap biotech's ateganosine-plus-cemiplimab regimen controlled disease in 38 of 43 evaluable late-line lung cancer patients, but no filing or timeline has been announced.
MAIA Biotechnology is positioning its lung cancer combination for a possible shortcut to the US market. On 17 November 2026 the company said fresh Phase 2 data could support an application to the Food and Drug Administration under the agency's accelerated approval pathway. It has not announced a filing and has not given a submission date.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): MAIA Biotechnology, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.